Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Sulfur – selenium or tellurium compound
Reexamination Certificate
2005-07-26
2005-07-26
Clardy, S. Mark (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Sulfur, selenium or tellurium compound
C514S532000, C514S570000, C514S717000, C514S730000, C514S859000, C514S863000, C514S885000, C514S886000, C514S887000
Reexamination Certificate
active
06921777
ABSTRACT:
The invention relates to novel heteroethynylenic compounds having the general formula (I):as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.
REFERENCES:
patent: 0 679 630 (1995-11-01), None
patent: 0 776 885 (1997-06-01), None
Remington's Pharmaceutical Sciences (17thEd. 1995), pp. 435-450.
Hoyos et al., Abstract Only; “Activation of c-Raf Kinase by Ultraviolet Light, Regulation by Retinoids”; J Biol Chem; 2002, pp. 23949-23957; vol. 277; No. 26; American Society for Biochemistry and Molecular Biology; Baltimore, Maryland, USA.
Saurat; Abstract Only; “Skin, Sun, and Vitamin A: From Aging to Cancer”; J Dermatol; 2001; pp. 595-598; vol. 28; No. 11; Japanese Dermatological Association, Tokyo, Japan.
Griffiths; Abstract Only; “The Role of Retinoids in the Prevention and Repair of Aged and Photoaged Skin”; Clin Exp Dermatol; 2001; pp. 613-618; vol. 26; No. 7; Blackwell Publishing, Oxford, United Kingdom.
Ruiz-Maldanado et al.; Abstract Only; “The Use of Retinoids in the Pediatric Patient”; Dermatol Clin; 1998; pp. 553-569; vol. 16; No. 3; WB Saunders Company, Philadelphia, PA, USA.
Virtanen; Abstract Only; “Phenotypic/Genotypic Correlations in Patients with Epidermolytic Hyperkeratosis and the Effects of Retinoid Therapy on Keratin Expression”; Acta Derm Venereol; 2001; pp. 163-170; vol. 81; No. 3; Taylor & Francis, London, United Kingdom.
Gunther; Abstract Only; “Vitamin A Acid in Darier's Disease”; Acta Derm Venereol Suppl; 1975; pp. 146-151; vol. 74; Taylor & Francis, London, United Kingdom.
Zouboulis; Abstract Only; “Retinoids—Which Dermatological Indications will Benefit in the Near Future?” Skin Pharmacol Appl Skin Physiol; 2001; pp. 303-315; vol. 14; No. 5; Karger AG, Basel Switzerland.
Peck et al.; “Synthetic Retinoids in Dermatology”; The Retinoids: Biology, Chemistry, and Medicine 2nd Edition; Edited by Sporn et al.; 1994; Chapter 16, pp. 631-658; Raven Press Ltd., New York, New York, USA.
Cheng; “Topical Retinoids in Dermatology”; Medical Progress; 1999; pp. 15-20; Butterworth, London, United Kingdom.
C. Maignan et al, Bull. Soc. Chim. Fr., No. 4, 1986, pp. 645-649, XP002114593, p. 647, col. 2, composé 3a; p. 648, col. 2, composé 3YE.
Database Chemabs “Online”, Chemical Abstracts Service, Columbus, Ohio, STN, CAPLUS, Accession No. 1981:550094, XP002114599 abrégé; RN 79354-19-1 & E.Y. Kolosov et al, Zh.Org.Khim., vol. 17, No. 6, 1981, pp. 1184-1190.
Database Chemabs “Online”, Chemical Abstracts Service, Columbus, Ohio, STN, CAPLUS, Accession No. 1976:523496, XP002114600 abrégé; RN 60983-97-3 & L.A. Bez'yazychnaya et al, Zh. Obshch. Khim., vol. 46, No. 7, 1976, pp. 1557-1566.
R. S. Paley et al, J. Org. Chem., vol. 62, No. 18, 1997, pp. 6326-6343, XP002114594, p. 6335, composé 7d; p. 6336, composés 10c, 10g; p. 6338, composés 15a, 16a.
X. Huang et al: Synthesis, No. 10, 1996, pp. 1191-1192, XP002114595, p. 1192, composé 5d.
G. Solladie et al, Synthesis, No. 11, 1991, pp. 1011-1012, XP002114596, p. 1011, composés 3a-b.
J. Barluenga et al, J. Chem. Soc. Perkin Trans 1, No. 12, 1987, pp. 2605-2609, XP002114597, p. 2606, composé 19.
M.C. Barnabeu et al, Tetrahedron Lett., vol. 36, No. 22, 1995, pp. 3901-3904, XP002114598, p. 3902, composés 1a-c.
M.C. Barnabeu et al, Tetrahedron Lett., vol. 37, No. 20, 1996, pp. 3595-3598, XP004029356.
Database Chemabs “Online”, Chemical Abstracts Service, Columbus, Ohio, US, STN, CAPLUS, Accession No. 1972:501313, XP002114939, abrége; RN 38276-74-3 & Chemical Abstracts, vol. 77, No. 15, Oct. 9, 1972, Columbus, Ohio, US; Abstract No. 101313z, abrégé & E. Schmid et al: Helv. Chim. Acta, vol. 55, No. 5, 1972, pp. 1625-1674.
STN/CAS online, file CAPLUS, Acc. No. 1993:625606, Doc. No. 119:225606, (Houpis et al., Synlett (1993), (5), 365-6), Abstract.
Bernardon Jean-Michel
Diaz Philippe
Choi Frank
Clardy S. Mark
Galderma Research & Development S.N.C.
LandOfFree
Heteroethynylenic compounds and pharmaceutical and cosmetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroethynylenic compounds and pharmaceutical and cosmetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroethynylenic compounds and pharmaceutical and cosmetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397165